公司資料
Sagimet Biosciences 股價、新聞與催化劑
- 股票代碼:
- SGMT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
10.43 USD (-1.14%)
收盤價
最後更新: 2026年8月17日
419M USD
市值
股價為何變動
The latest monitored company update is “Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).” The corresponding closing-price reaction is not yet available.
公司概覽
Metabolic Pathway Therapeutics
Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production.
Denifanstat
Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology.
Dermatology Focus
Sagimet is prioritizing moderate-to-severe acne, where reduced sebaceous lipid synthesis may address an upstream disease mechanism.
未來催化劑
- A U.S. Phase 3 study of denifanstat in moderate-to-severe acne is planned to begin in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。